Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Eikon Therapeutics Inc

EIKN ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Small Cap Analyst: BUY

Last Close

$11.16

▼ -2.02%

Market Cap $604.48M · Vol 129.26K

Key Metrics

P/E Ratio

0.21

FWD: N/A

Market Cap

$604.48M

Small Cap

Div Yield

N/A

EPS Growth

N/A

YoY

RSI (14)

62.08

Momentum

Beta

N/A

vs Market

52W High

$17.32

35.57% below

52W Low

$7.92

40.91% above

Volume

129.26K

Avg 119.89K

P/B

N/A

Price-to-book

ROE

N/A

Return on equity

Free Float

75.87%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Eikon Therapeutics Inc (EIKN) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does EIKN pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+6.59%

+25.39%

+2.29%

-25.10%

YTD

N/A

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-324,248,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-59.72% · N/A

P/E Ratio	0.21
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	N/A
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	54.17M

Technical Indicators

50-Day SMA	$10.29
200-Day SMA	$N/A
RSI (14)	62.08
Beta	N/A
52-Week High	$17.32
52-Week Low	$7.92

Volume Today	129.26K
Avg Daily Volume (30D)	119.89K
Relative Volume	1.08x
Volatility (10D)	96.00
Volatility (30D)	79.39
Free Float	75.87%

Analyst Consensus

BUY

Current Price $11.16

Mean Target $23.50

52W Low$7.92 52W High$17.32

Current

Target

$7.92 $17.32

Current Analyst target

+110.57% upside potential · 6 analysts

Identifiers

ExchangeNasdaq

FIGIBBG00T0XRJ84

ISINUS2825641036

CountryUnited States of America

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateNov 13, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG -0.74% RVMD Revolution Medicines Inc +1.01% ONC BeOne Medicines AG -0.66% 068270.KS Celltrion Inc +0.88% ABVX Abivax SA +1.04%

Company Profile

Eikon Therapeutics, Inc. is a late-stage clinical biopharmaceutical company, which is focused on advancing a pipeline of potential therapies for patients with unmet medical needs. The Company has clinical programs at various stages of development, and active discovery efforts in oncology and neurological disease. Its pipeline includes EIK1001 TLR7/8 Melanoma, EIK1001 TLR7/8 NSCLC, EIK1003 PARP1, EIK1004 PARP1, EIK1005 WRN Phase 1, EIK1006, and AR-V7. EIK1001 is a systemically administered dual-agonist of toll-like receptors 7 and 8 that has demonstrated single-agent activity, as well as activity in combination with anti-PD-(L)1 agents, across multiple solid tumor types in Phase 1 trials. EIK1003 targets PARP1, a central component of DNA repair machinery in normal cells. EIK1003 is being evaluated in a Phase 1/2 study of patients with breast, ovarian, or prostate malignancies that have known or suspected deleterious mutations of select homologous recombination repair (HRR) genes.